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Although proton therapy was developed almost 80 years ago, widespread 
clinical implementation has been limited until the past decade. With the growing 
use of proton therapy, there is a desire to prove the equivalence or superiority of 
proton therapy across a number of cancer disease sites. Dozens of clinical trials 
have been developed to accomplish this within individual institutions, among a few 
centers, and across national and international networks such as the National Cancer 
Institute’s National Clinical Trial Network. The protocols include proton therapy 
imbedded in trials with photon therapy as well as randomized photon vs. proton 
trials. This chapter provides an overview of the design of such trials as well as some 
of the challenges facing protocols with proton therapy.
Keywords: proton therapy, clinical trials, protocols, randomized, phase II, phase III, 
National Cancer Institute, National Clinical Trial Network
1. Introduction
1.1 Clinical trial importance
Clinical trials are an important step to ensuring the safety and efficacy of 
medical treatment. For radiation therapy, clinical trials have allowed us to look 
at important questions like dose escalation, fractionation, and new radiotherapy 
technologies. Much like the use of instensity-modulated radiation therapy (IMRT) 
was critically reviewed in the early 2000s, proton therapy has come under careful 
scrutiny over the past decade. Many radiation therapy departments commissioned 
proton therapy centers and began to integrate protons into their clinical practice.
1.1.1 Safety and efficacy
Most people who work in radiation therapy have seen the striking treatment plan 
comparisons between proton therapy and traditional photon therapy for a pediatric 
craniospinal case, noting the marked reduction in dose to organs at risk and normal 
tissue outside of the target region [1]. These in-silico studies are even more exciting 
given the potential reduction in secondary cancer for pediatric patients. The poten-
tial benefits in these studies come with corresponding risk; if the beam modeling 
or treatment delivery positioning is not accurate, there is a risk of high overdose to 
normal tissue or severe underdose of the target. For this reason, the National Cancer 
Institute (NCI), the American Society for Radiation Oncology (ASTRO), and other 
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groups have encouraged methodical, careful study of the clinical benefits of proton 
therapy through clinical trials [2].
The potential benefits of proton therapy are also complicated by the higher 
biological effectiveness of protons as compared with photons. The current clinical 
practice in the US is to use a relative biological effectiveness (RBE) of 1.1 for pro-
tons, but studies have shown that the true biological response is more complicated 
and variable [3]. While the higher RBE of protons is a potential benefit for killing 
tumor cells, there is potential increased biological risk to critical organs proximate 
to the target. Clinical trials with proton therapy can allow us to look at both sides of 
the coin by analyzing the correlation between RBE and clinical outcomes.
1.1.2 Evidence for insurance
Insurance companies have played a role in driving the development of random-
ized proton vs. photon clinical trials as well. Due to the higher up-front cost of 
proton therapy for many disease sites, insurance companies have asked for data 
showing marked improvement in survival outcomes for patients treated with 
proton therapy in order to cover treatment costs. As discussed later in the chapter, 
this presents a bit of a catch-22 in clinical trial accrual, as insurers are waiting for 
trial data to approve coverage, but trial data is nearly impossible to collect without 
insurance coverage for patients enrolled on-study.
1.2 Clinical trial landscape in the US
1.2.1 Clinical trial groups
The largest clinical trial system that supports proton therapy protocols in the US 
is the National Clinical Trial Network (NCTN), funded by the NCI. The NCTN is 
made up of four adult and one pediatric clinical trial groups, as well as a partnership 
with the Canadian Cancer Trials Group. Most of the proton therapy studies run 
through the NCTN are large-scale, multi-institutional Phase II and Phase III trials. 
These trials either randomize patients to proton or photon therapy to compare treat-
ment outcomes or imbed proton therapy as a possible treatment modality in a study 
designed to answer a different clinical question. The NCI has also funded proton 
clinical trials outside of the NCTN [4–7]. These are often run by a single proton 
center “sponsor” in partnership with other proton facilities and funded through 
NCI grants.
Outside of the NCI, there are several other groups that help sponsor clinical 
trials for proton therapy. The National Association for Proton Therapy (NAPT) is a 
nonprofit group that helps facilitate proton therapy research collaborations. Most 
of the operational proton therapy centers in the US are members of NAPT. The 
Patient-Centered Outcomes Research Institute (PCORI) provides funding for clini-
cal trials comparing proton vs. photon therapy for prostate and breast treatment. 
The NCI also has a Childhood Cancer Data Initiative (CCDI) that collects standard 
patient data, including proton therapy data, in a central repository for data sharing 
and analysis within the research community.
Outside of the US, several groups in Europe and Asia have proton therapy 
protocols open or in development. The Japan Clinical Oncology Group (JCOG) 
is funded by Japan’s National Cancer Center Research and Development Fund 
and conducts studies with proton therapy [8]. The European Organization for 
Research and Treatment of Cancer (EORTC) operates clinical trials within Europe 
and currently has two protocols with proton therapy embedded [9]. The European 
Society for Radiotherapy (ESTRO) recently established the European Particle 
3
Clinical Trials Evaluating Proton Therapy
DOI: http://dx.doi.org/10.5772/intechopen.95957
Therapy Network (EPTN), which conducts a number of prospective studies 
looking at proton (and carbon) therapy, and works in concert with the EORTC 
[10, 11]. Global collaborations on clinical trials have been limited so far. The US 
has the largest catalog of proton therapy clinical trials and has sought participa-
tion of international proton centers, but the many steps to opening the protocols 
(NCTN membership, state department clearance, baseline approval quality 
assurance) have slowed down collaboration. The clinical trial groups are working 
on streamlining these processes to allow for expanded international partnerships 
in the future.
2. Randomized proton vs. photon trials
In order to move past in-silico studies that promise superior dosimetry with 
proton therapy, clinical evidence is needed. One of the best ways to get these data 
are through randomized clinical trials. For proton therapy trials, randomization 
is generally structured with two arms: proton vs. photon. In order to get enough 
patients for statistical significance, these trials require a lot of patients (usu-
ally hundreds) and are typically run as multi-institutional studies. These large 
randomized studies may be designed to show superiority of proton therapy or to 
demonstrate non-inferiority [12]. Most NCTN randomized proton vs. photon trials 
have a primary endpoint of assessing overall survival. Secondary endpoints include 
progression-free survival, local control, toxicities, cognitive outcomes, symptoms 
burden, quality of life, cost effectiveness, and cost–benefit economics. While 
proton therapy generally has a higher up-front cost, it is hypothesized that proton 
therapy may be more cost-effective for some disease sites due to reduction in acute 
and long-term toxicities and associated medical costs.
Typically NCTN clinical trial data is only assessed for objectives explicitly listed 
in the protocol and analysis outside the original scope is only permitted after the 
trial has been closed several years. For this reason, somewhat indefinite exploratory 
objectives are written into the protocol to allow for analyses that may not be under-
stood at the time of protocol development. For randomized proton vs. photon trials 
within the NCTN, exploratory objectives include biospecimen and imaging data 
collection for the assessment of biomarkers.
Most randomized proton vs. photon studies randomize 1:1, though some 
protocols have randomize 2:1 in favor of proton therapy. The two arms typically 
have the same radiobiological dose prescription, though some studies like NRG 
Oncology/RTOG 1308 have low dose and high dose arms.
2.1 Challenges of randomized proton vs. photon trials
Clinical trials can be challenging for a number of reasons - increased personnel 
effort to coordinate patient enrollment and data submission, increased operational 
costs, low patient interest, and low physician engagement – but randomized proton 
vs. photon trials face a number of unique challenges.
2.1.1 Treatment planning
One unique aspect of proton vs. photon trials is that it is common to create 
treatment plans for patients using both modalities to ensure that both can meet the 
planning dose constraints required by the protocol [13]. This may require increased 
time on the part of the participating institutions, though many proton centers may 
already be creating double plans for insurance purposes.
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Treatment planning itself is different between proton therapy and photon 
therapy. The planning target volume (PTV) that is commonly used for photon 
plans is generally not used in the same way for proton therapy. Instead of uniform 
expansion from clinical target volume (CTV) to the PTV, proton treatment plans 
may have one pre-defined lateral margin, and a different margin in the direction of 
the beam range that depends on the maximum beam energy [14, 15]. In this way, 
the proton “PTV” is beam-specific. This presents a challenge for clinical trial data 
analysis, as most protocols are written with historical photon PTV constraints. 
Future protocols should be designed with this in mind.
Furthermore, proton therapy treatment planning has started to shift away from 
the standard lateral and range margins in favor of robust optimization of the CTV 
[16, 17]. There are many different ways to report dose when using robust optimiza-
tion (e.g. voxel-wise worst-case approach, scenario-wise worst-case approach, 
delivered dose variance) [18]. Clinical trials should soon consider how robustly 
optimized treatment planning data will be collected to ensure appropriate data 
comparison between the proton and photon arm. This highlights the crucial role 
that physicists and data (i.e. Digital Imaging and Communications in Medicine 
(DICOM)) experts play in the development of clinical trials.
In addition to the nuances of physical dose, randomized proton vs. photon 
trials need to consider the implications of radiobiology. The NCTN currently uses 
an RBE of 1.1, but many proton centers are starting to consider variable RBE in 
their treatment planning practices [19, 20]. If variable RBE treatment planning 
becomes standard, clinical trials will need to incorporate it into treatment planning 
constraints, and determine what patient data needs to be collected to appropriately 
compare different treatment plans.
2.1.2 Patient preference
One challenge with randomized clinical trials comparing proton therapy with 
photon therapy is patient preference. This manifests when a patient is randomized 
to one arm but has a strong desire to be treated on the other arm, and thus goes 
off protocol. Patients randomized to the photon arm may decide they want proton 
therapy instead due to an impression gathered through independent online research 
or a preference for the “latest and greatest” technology. Conversely, some patients 
randomized to the proton arm may go off protocol to receive photon therapy due to 
mistrust of a new, “unproven” technology.
2.1.3 Insurance denial
Another challenge of proton trial accrual is insurance denial for proton therapy 
[21]. This is particularly challenging in the case of randomized proton vs. photon 
trials because it can make it harder to reach accrual goals on the proton arm of the 
protocol. Insurance denials of proton therapy can also skew the patient demograph-
ics of the proton arm. For example, Medicare is significantly more likely to cover 
proton therapy than private insurers, which can skew the age of the proton cohort 
toward older participants [22]. This older patient cohort might have comorbidities 
or other characteristics that make it challenging to compare outcomes data between 
the two arms. Lastly, the process of appealing insurance denials can lead to delays in 
the start of radiation treatment [23]. Clinical trial patients may already wait slightly 
longer for treatment to start due to clinical trial requirements such as pre-treatment 
reviews of the treatment plan. These delays might result in a patient going off trial 
to pursue treatment sooner.
5
Clinical Trials Evaluating Proton Therapy
DOI: http://dx.doi.org/10.5772/intechopen.95957
One way to counteract the deleterious effect of proton insurance denial on 
randomization is to use a 2:1 randomization in favor of proton therapy. This gives 
the trial more opportunities to accrue proton patients, even if insurance challenges 
persist. But most proton centers choose to challenge insurance denials, and the 
best way to combat insurance denial is through support networks and sharing of 
resources. The NAPT offers a guide for patients on steps to deal with insurance 
denial, many of which are applicable to clinical teams as well [24]. Many proton 
centers have dedicated personnel to manage insurance appeals. For the NCTN, 
proton insurance denials are a frequent topic at operations management and proton 
working group meetings. These forums allow physicians to share successful tech-
niques to overcome insurance barriers. Physicians have banded together to publish 
pleas for insurance companies to change the insurance approval process for proton 
therapy [25]. Some proton therapy centers have negotiated with insurance compa-
nies to reimburse proton therapy at the cost of IMRT, picking up the rest of the costs 
themselves [25]. The NCI has also advocated on behalf of proton therapy centers 
in the context of clinical trial insurance reimbursement for randomized NCTN 
protocols [26].
2.1.4 Logistics of partnerships with proton centers in other cities, countries
Due to the limited number of proton therapy centers, many randomized 
proton vs. photon trials encourage partnerships between one proton center and 
any number of photon clinics. There are many considerations when establishing 
a partnership between two institutions, such as who gets “credit” for the clinical 
trial accrual, how clinical trial reimbursement is allocated between the institutions, 
which personnel have rights to upload patient data to the appropriate portals, etc. 
There is a possibility that a photon clinic might partner with a proton center in 
another country. In this case, the logistics of travel reimbursement (if provided) 
should be addressed, as well as clinical trial membership and state approval if the 
trial is run through the NCTN. This type of partnership may become increasingly 
common as clinical trials for carbon therapy are being developed, with most carbon 
centers located in Europe and Eastern Asia. A few concepts have been proposed 
that randomize IMRT treatment to centers in the US, and carbon therapy to centers 
abroad [27].
3. Imbedded proton trials
In addition to randomized proton vs. photon clinical trials, there are a number 
of trials that imbed proton therapy as one of several allowed treatment modalities. 
This practice was most common this past decade in pediatric trials, such as those 
conducted by the Children’s Oncology Group (COG), but has been applied to adult 
trials as well. While the superiority of proton therapy outcomes might not be the 
primary endpoint of these studies, the hope is that with enough data, secondary 
analyses can be performed to look at proton patient cohorts compared to others.
3.1 Pediatric trials
To date, the standard method of including proton therapy in pediatric clinical 
trials has been to imbed protons in the protocols. The strategy recognizes the chal-
lenges of accrual to disease-specific radiation therapy protocols in pediatric patients 
and permits parallel treatment strategies for both photon and proton care to 
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successfully manage the study. Approximately 50% of pediatric malignancies are in 
the leukemia domain, therefore protocols requiring radiation therapy are directed 
to tumors of the central nervous system, sarcoma, renal, orbit including retino-
blastoma, and lymphoma. Therapy volumes and target dose are uniform between 
proton and photon care with guidelines imbedded in the study to insure synergistic 
care for tumor control acknowledging subtle differences in planning target volumes 
and dose distribution to normal tissue. Both proton and photon patients need to 
meet the identical dose to tumor and normal tissue. Dose to normal tissue in most 
situations is more easily achieved with proton therapy. In pediatric studies, outcome 
analysis including imaging are part of the longitudinal aspect of protocol manage-
ment, therefore colleagues in the COG and the Imaging and Radiation Oncology 
Core (IROC) can evaluate normal tissue endpoints with outcome imaging valida-
tion to review comparison plans in retrospect to acquire important outcome analysis 
for secondary study endpoints between proton and photon care.
One challenge pediatric trials have faced is the apparent racial disparities 
between who receives proton therapy, with non-Hispanic white pediatric patients 
significantly more likely to be treated with protons than black patients [28]. This 
presents a challenge to proportional racial representation in clinical trial data.
3.2 Adult trials
In the US, adult clinical trial groups have imbedded proton therapy in dozens 
of clinical trials. At times, proton therapy has been added through clinical trial 
amendments with the hope of boosting accrual to protocols struggling to accrue 
patients. For a number of reasons (small number of proton centers, insurance 
denials, competing proton-specific trials), this has not proven to be the silver 
bullet, however, and generally it’s not recommended to add proton therapy as 
an allowable modality solely to improve trial accrual for adult protocols. Despite 
lower accrual numbers, proton therapy can be a good addition to a trial, adding the 
possibility of secondary analyses to look at proton therapy outcomes in relation to 
other treatment modalities.
4. Proton therapy registries
Outside of prospective clinical trials with proton therapy, there are a number 
of proton therapy registries. These are generally less structured than Phase II/
Phase III trials and allow for more flexibility in which data are analyzed. The Proton 
Collaborative Group (PCG) is a registry of nearly six thousand proton patients in 
the US [29]. The PCG looks at survival outcomes and quality of life, and fosters peer 
review collaboration across centers for clinical trial development. The Pediatric 
Proton Consortium Registry (PPCR) is a multi-institutional collaborative registry 
of demographic and clinical data for pediatric patients treated with proton and pho-
ton therapy [30]. The goal of the PPCR is to compare benefits of the two radiother-
apy techniques, such as disease outcomes and quality of life. Washington University 
School of Medicine and Radialogica, LLC have a Proton Therapy Registry for adult 
and pediatric patients that collects clinical and dosimetric data [31].
5. Conclusions
Proton therapy has great potential and in some cases, proven clinical benefit. 
The best way to gather evidence to secure proton therapy as a standard of care for 
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cancer treatment is through thoughtful, controlled clinical trials. Much work has 
already been done to this effect, and with so many clinical trials for proton therapy 
currently accruing, we will soon have data to answer the myriad questions related to 
proton therapy treatment outcomes.
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